Coeliac disease is one of the commonest autoimmune conditions affecting the developing world, with 1% of the population believed to be affected.
Characterised by an intolerance to gluten, there are no medicinal treatments available for the condition and patients adhere to a strict gluten-free diet to ensure the avoidance of symptoms, which include nausea, stomach cramps, and diarrhoea. In spite of this, accidental gluten consumption affects 90% of coeliac patients every month, and correlates to gastrointestinal aberrations in many patients.
At CelerX, we have conceptualised a prophylactic microbiome-based solution that provides constitutive protection against the problem of accidental gluten contamination. Presently, we are leveraging our technology to address unmet medical need in the coeliac disease market, however our ultimate goal is to apply our concept to a multitude of gastrointestinal conditions.